Rocket


Overview
Financials
News + Filings
Key Docs
Insiders

 
 

Apellis Pharmaceuticals, Inc. (APLS) Add to portfolio


Recent News + Filings   (All items)

Financial Summary   (All financials)
In millions, except per share itemsDec-31-21Dec-31-20Dec-31-19Dec-31-18Dec-31-17Dec-31-16Dec-31-15Dec-31-14
Revenues66.6250.60.00.00.00.00.08.4
            Revenue growth-73.4%     -100.0%261.6%
Cost of goods sold0.20.00.00.00.00.00.016.8
Gross profit66.4250.60.00.00.00.00.0-8.4
            Gross margin99.7%100.0%     -100.0%
Research and development345.9299.9221.0105.340.323.013.7 
General and administrative176.8139.467.022.610.54.36.42.9
EBIT-536.3-213.7-288.0-127.9-50.8-27.3-20.1-11.3
            EBIT margin-805.7%-85.3%     -134.8%
Pre-tax income-746.0-343.0-304.7-127.5-51.0-27.1-46.5-11.2
Income taxes0.41.80.00.00.00.00.0-0.4
            Tax rate  0.0%0.0%0.0%0.0%0.0%3.9%
Net income-746.4-344.9-304.7-127.5-51.0-27.1-46.5-10.8
            Net margin-1121.3%-137.6%     -128.7%
 
Diluted EPS($8.84)($4.59)($4.90)($2.34)($3.68)($3.22)($8.03)($1.10)
Shares outstanding (diluted)84.475.262.254.413.98.45.89.8
 
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy